每经头条（nbdtoutiao）——5年增长33倍，这类新险种卖爆了，身边很多人都需要，30多家险企蜂拥而 入⋯⋯ （记者 王晓波） 每经AI快讯，陇神戎发（SZ 300534，收盘价：9.65元）9月26日晚间发布公告称，甘肃陇神戎发药业股 份有限公司董事会于近日收到公司财务总监赵正财先生的书面辞职报告，因工作调整，赵正财先生申请 辞去公司财务总监职务及兼任的子公司甘肃药业集团运营有限公司财务总监职务，辞职后将在公司控股 股东处任职，不再担任公司及子公司任何行政职务，赵正财先生原定任期为2024年1月3日至2027年1月2 日。经公司总经理提名、公司董事会提名委员会、审计委员会审查并审议通过，公司董事会同意聘任肖 荣女士为公司财务总监。 2025年1至6月份，陇神戎发的营业收入构成为：药品销售占比86.53%，医疗器械销售占比6.69%，物流 配送占比4.48%，房屋租赁占比0.76%，提供咨询占比0.7%。 截至发稿，陇神戎发市值为29亿元。 ...

证券代码：300534 证券简称：陇神戎发 公告编号：2025-067 甘肃陇神戎发药业股份有限公司 关于公司财务总监辞职暨聘任财务总监的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、关于公司财务总监辞职的情况 甘肃陇神戎发药业股份有限公司（以下简称"公司"）董事会于近日收到公 司财务总监赵正财先生的书面辞职报告，因工作调整，赵正财先生申请辞去公司 财务总监职务及兼任的子公司甘肃药业集团运营有限公司财务总监职务，辞职后 将在公司控股股东处任职，不再担任公司及子公司任何行政职务，赵正财先生原 定任期为 2024 年 1 月 3 日至 2027 年 1 月 2 日。 截至本公告披露日，赵正财先生未持有公司股份，亦不存在应当履行的股份 锁定承诺。根据《公司法》等法律法规以及《公司章程》的有关规定，赵正财先 生的辞职报告自送达公司董事会之日起生效，赵正财先生所负责的工作已全部完 成交接，其辞职不会影响公司的正常经营。 公司董事会对赵正财先生在任职期间勤勉尽责的工作和为公司所做出的贡 献表示衷心的感谢！ 二、聘任财务总监的情况 公司于 2025 年 9 月 ...

第五届董事会第二十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 甘肃陇神戎发药业股份有限公司（以下简称"公司"）第五届董事会第二十 一次会议于 2025 年 9 月 26 日以通讯表决方式召开，本次会议以豁免通知时限形 式于 2025 年 9 月 25 日以电子邮件等形式通知全体董事。本次会议由公司董事长 康永红先生主持，应出席会议董事 9 人，实际出席会议董事 9 人，公司高级管理 人员列席了会议。本次会议的召集、召开符合《公司法》等有关法律、行政法规、 部门规章和《公司章程》的相关规定，合法有效。 二、董事会会议审议情况 会议审议并通过了如下议案： 证券代码：300534 证券简称：陇神戎发 公告编号：2025-066 甘肃陇神戎发药业股份有限公司 甘肃陇神戎发药业股份有限公司董事会 2025 年 9 月 26 日 1.审议通过《关于聘任公司财务总监的议案》 经审议，同意聘任肖荣女士为公司财务总监，任期自本次董事会审议通过之 日起至第五届董事会届满之日止。肖荣女士的任职资格已经公司董事会提名委员 会、审计委员会审 ...

Core Viewpoint - Longshen Rongfa (300534.SZ) announced that its subsidiary, Gansu Puan Pharmaceutical Co., Ltd., received a new drug production license from the Gansu Provincial Drug Administration, effective September 25, 2025, due to the application for the reduction of commissioned production of a specific medicine [1] Group 1 - The change in the drug production license is primarily due to the application for the reduction of the commissioned production of Xuanfei Zhiso Decoction (National Drug Approval Number Z20050288) [1] - The completion of the license change procedures is in accordance with legal requirements and will not have a significant impact on the company's production and operations [1] - Investors are advised to make cautious decisions and pay attention to investment risks [1]

Core Viewpoint - The company announced that its subsidiary, Gansu Puan Pharmaceutical Co., Ltd., has successfully completed the renewal process for its Drug Production License, which was approved by the Gansu Provincial Drug Administration on September 25, 2025. The renewal is primarily due to the application for the reduction of the commissioned production of the cough syrup (National Medicine Standard Z20050288) and is not expected to have a significant impact on production and operations [1]. Summary by Categories - **Company Update** - Gansu Puan Pharmaceutical Co., Ltd. has received a renewed Drug Production License from the Gansu Provincial Drug Administration [1]. - The renewal process was completed on September 25, 2025 [1]. - **Operational Impact** - The change in the Drug Production License is related to the application for the reduction of commissioned production of a specific cough syrup [1]. - The company has completed the necessary legal procedures for this change, which is not anticipated to significantly affect its production and operations [1].

甘肃陇神戎发药业股份有限公司（以下简称"公司"）控股子公司甘肃普安 制药股份有限公司（以下简称"普安制药"）因申请核减药品委托生产相关事项 办理了《药品生产许可证》换发手续，于 2025 年 9 月 25 日收到由甘肃省药品监 督管理局核准换发的《药品生产许可证》，现将有关情况公告如下： 一、换发后的《药品生产许可证》基本信息 企业名称：甘肃普安制药股份有限公司 证券代码：300534 证券简称：陇神戎发 公告编号：2025-065 社会信用代码：91620600762352467T 甘肃陇神戎发药业股份有限公司 关于控股子公司取得换发后的《药品生产许可证》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 生产地址和生产范围：甘肃省武威市凉州区黄羊生态工业（食品）示范园农 大北路 1 号：合剂，膜剂，原料药（盐酸纳洛酮），前处理、提取*** 有效期至：2026 年 3 月 2 日 许可证编号：甘 20160089 分类码：AhzDh 日常监督管理机构：甘肃省药品监督管理局 注册地址：甘肃省武威市凉州区黄羊生态工业（食品）示范园农大北路 1 号 法定代表人 ...

Core Viewpoint - The stock of Longshen Rongfa has shown a mixed performance in recent trading sessions, with a year-to-date increase of 12.12% but a decline of 3.00% in the last five days and 6.36% over the past 20 days [2] Company Overview - Longshen Rongfa Pharmaceutical Co., Ltd. is located in Yuzhong County, Lanzhou, Gansu Province, established on June 3, 2002, and listed on September 13, 2016 [2] - The company's main business involves the production and sales of traditional Chinese medicine, with revenue composition as follows: 86.53% from drug sales, 6.69% from medical devices and others, 4.48% from logistics, and smaller contributions from rental, consulting, and other services [2] Financial Performance - For the first half of 2025, Longshen Rongfa reported operating revenue of 496 million yuan, a year-on-year decrease of 9.91%, while net profit attributable to shareholders increased by 30.31% to 27.96 million yuan [2] - Cumulative cash dividends since the company's A-share listing amount to 42.64 million yuan, with 24.27 million yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders is 27,800, a decrease of 0.71% from the previous period, with an average of 10,853 circulating shares per person, an increase of 0.71% [2] - Among the top ten circulating shareholders, the Huatai-PineBridge CSI Traditional Chinese Medicine ETF holds 978,500 shares, down by 101,600 shares from the previous period [3] Market Activity - On September 24, the stock price increased by 2.10% to 9.71 yuan per share, with a trading volume of 45.17 million yuan and a turnover rate of 1.55%, resulting in a total market capitalization of 2.945 billion yuan [1] - The net inflow of main funds was 1.57 million yuan, with significant buying activity from large orders [1]

（编辑 楚丽君） 证券日报网讯 9月19日晚间，陇神戎发发布公告称，近日，甘肃陇神戎发药业股份有限公司控股子公司 甘肃普安制药股份有限公司取得甘肃省药品监督管理局核准签发的《药品上市前现场核查及首批产品检 验登记件》，药品名称：通脉口服液。 ...

Group 1 - Huadian Co., Ltd. plans to issue H-shares and list on the Hong Kong Stock Exchange [2] - Cisco Ray's 2022 annual report was found to have inflated revenue by 9.96 million and profit by 7.0054 million, leading to penalties and a change in stock name to ST Cisco Ray [3] - Tianpu Co., Ltd. experienced a 245.20% increase in stock price over 13 consecutive trading days, indicating a risk of rapid decline [4] - ST New Power is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws [6] - Baoli International intends to invest in semiconductor testing equipment company Hongtai Technology, acquiring 1%-3% equity [7] - Ankai Micro plans to invest 20 million yuan to acquire 4% equity in Shiqi Future, focusing on smart vision technology [8] Group 2 - SF Holding reported a revenue of 24.787 billion yuan in August, a year-on-year increase of 7.86% [9] - Various companies are involved in share transfers, including Guangli Micro and *ST Tianlong, with plans for significant asset restructuring [11] - Xinwangda's subsidiary aims to establish a storage industry fund with professional investment institutions [12] - Several companies are planning share repurchases, including Shunhao Co. and Lingyun Optics, with adjustments to repurchase plans [18]

智通财经APP讯， 陇神戎发(300534.SZ)公告，公司控股子公司甘肃普安制药股份有限公司取得甘肃省 药品监督管理局核准签发的《药品上市前现场核查及首批产品检验登记件》。通脉口服液通过了药品生 产现场检查、技术审评，所抽样品(批号：CP022250701)经省药检院检验符合规定，可上市销售。通脉 口服液功能主治活血通脉，用于缺血性心脑血管疾病，动脉硬化，脑血栓，脑缺血，冠心病，心绞痛。 ...